Symbiotec Pharmalab’s Rs 1,757 crore IPO opened August 24, with a Rs 938–988 price band and 41% grey-market premium. The issue combines fresh shares and an OFS, while proceeds will partly repay debt. Its specialised API manufacturing, regulatory approvals and biotechnology capabilities offer investors exposure to India’s pharmaceutical manufacturing growth.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.